ArticleJAMA network open2024
Respiratory Syncytial Virus Hospital-Based Burden of Disease in Children Younger Than 5 Years, 2015-2022.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- CAUSAL-RSV: A study protocol for a causal mediation analysis of RSV vaccine effects in infants using real-world data.medRxiv : the preprint server for health sciences · 2026Article
- Epidemiological Characteristics of Respiratory Syncytial Virus in Pediatric Acute Lower Respiratory Tract Infections in Baoding, Hebei Province of China, from 2017 to 2024.Children (Basel, Switzerland) · 2026Article
- Temporal trends in respiratory syncytial virus-related infant mortality and hospitalizations in the United States.Pediatric research · 2026Article
- Respiratory syncytial virus - from discovery to vaccines.Journal of medical microbiology · 2026Review
- Household Transmission and Genomic Diversity of Respiratory Syncytial Virus in the United States, 2022-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Severity of respiratory syncytial virus through the COVID-19 pandemic among infants aged ≤2 months: a secondary analysis of the IRIDE cohort study.Pediatric research · 2026Observational
- Observational
- Correlates of risk of respiratory syncytial virus disease: a prospective cohort study.Nature communications · 2025Article
- Shifts in Influenza and Respiratory Syncytial Virus Infection Patterns in Korea After the COVID-19 Pandemic Resulting From Immunity Debt: Retrospective Observational Study.JMIR public health and surveillance · 2025Observational
- Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.The Journal of infectious diseases · 2025Article
- Seasonal epidemiological and clinical characteristics of pediatric patients with respiratory syncytial virus infection by age during COVID-19: a cross-sectional study.Translational pediatrics · 2025Article
- Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus.JAMA network open · 2025Observational
- Structures of respiratory syncytial virus G bound to broadly reactive antibodies provide insights into vaccine design.Scientific reports · 2025Article
- Article
- Epidemiologic characteristics of immunoglobulin M antibodies in lower respiratory tract infection pathogens of children: association with severe pneumonia in Chengdu city from 2019 to 2023.American journal of translational research · 2025Article
- Article
- Article
- Postpandemic fluctuations of regional respiratory syncytial virus hospitalization epidemiology: potential impact on an immunization program in Switzerland.European journal of pediatrics · 2024Article
- Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.Infectious diseases and therapy · 2024Article
- Burden of Illness Associated With Respiratory Syncytial Virus, Influenza, and Coronavirus Disease 2019 in Infants and Young Children in Ontario, Canada, 2018-2023: A Population-Based Canadian Immunization Research Network Study.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Respiratory syncytial virus (RSV) resurgences have been noted following the COVID-19 pandemic in many countries. Recent findings suggest that the 2021 and 2022 RSV seasons were more severe than in past seasons, and age distribution may have shifted toward older children in the younger than 5 years age group. Objectives: To estimate age-specific changes in RSV hospital-based burden of disease before and after the COVID-19 pandemic and to compare incidence by Medicaid use. Design, Setting, and Participants: This retrospective cohort study included children younger than 5 years diagnosed with RSV and bronchiolitis at 50 US children's hospitals in 10 US geographic regions. The included participants had an encounter in intensive care, inpatient, emergency, or observational units, between June 1, 2015, and March 31, 2023. Exposures: Diagnosis of RSV, bronchiolitis, or both at encounter. Main Outcome and Measures: Incidence rate ratio of hospital use within each care unit before vs after the COVID-19 pandemic. It was hypothesized a priori that incidence of hospital use would increase overall in 2021 and 2022 compared with 2015 to 2019 and that the increase would be greater among children 12 months and older. Results: Of 924 061 study participants (median [IQR] age, 8 (5-16) months; 535 619 [58.0%] male), 348 077 (37.7%) were diagnosed with RSV. Of these, 187 850 (54.0%) were hospitalized. Incidence rate ratios of hospitalization increased for all ages in 2021 and 2022 compared with 2015 to 2019. Children aged 24 to 59 months were 4.86 (95% CI, 4.75-4.98) times as likely to be hospitalized in 2022 compared with 2015 to 2019, whereas infants aged 0 to 5 months were 1.77 (95% CI, 1.74-1.80) times as likely. Medicaid patients were more likely to be hospitalized than non-Medicaid patients regardless of year. Conclusions and Relevance: Hospitalizations for RSV and bronchiolitis demonstrated atypical seasonality in 2021 and 2022, with an overall increase in RSV encounters. Postpandemic RSV hospitalization increased for all ages, but especially among older children, whereas bronchiolitis hospitalization was decreased or unchanged compared with earlier seasons. These findings suggest some of the observed increase in RSV hospital use may be due to increased testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.